StockData

Invivyd vs Valneva

IVVD and VALN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

ivvdInvivyd$0.58−67.1% in 1 yearvalnValneva$5.66−38.4% in 1 year

How IVVD and VALN compare

Invivyd grew revenue faster over the last twelve months (26.3% versus −27.2% for Valneva).

Invivyd scores higher on the StockData Score (9 against 1 for Valneva), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIVVDVALN
Size and price
Market cap$172M–
Share price$0.582$5.66
Change, 1 year−67.1%−38.4%
Change, 5 years−97.1%−88.4%
Beta (5Y)1.411.67
Employees122140
StockData Score
Total score9 (better)1
Valuation score3 (better)0
Growth score1 (better)0
Performance score00
Health score5 (better)1
Dividend score00
Valuation
P/S2.9×–
P/B0.9×–
FCF yield−63.9%–
Fair value$0.954–
Margin of safety39.0%–
Growth
Revenue growth (TTM)26.3% (better)−27.2%
Revenue growth, 5Y average–9.6%
Profitability
Gross margin–16.4%
Operating margin−193%−80.5% (better)
Net margin−184%–
FCF margin−188%−40.6% (better)
Return on equity−95.9%–
Return on invested capital−616%–
Financial health
Debt / equity0.00–
Interest coverage–−2.8×
Current ratio5.87 (better)2.16
Altman Z-score−4.53–
Piotroski F-score5–
Dividends and buybacks
Buyback yield−0.23%–
Shareholder yield−0.23%–
Ownership
Held by institutions79.0%2.2%
Held by insiders16.7%11.0%
Insider net buying, 12 months−$531K–
Short interest, % of float14.7%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.